Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates

TA Weaver, AH Charafeddine, A Agarwal, AP Turner… - Nature medicine, 2009 - nature.com
TA Weaver, AH Charafeddine, A Agarwal, AP Turner, M Russell, FV Leopardi, RL Kampen…
Nature medicine, 2009nature.com
Memory T cells promote allograft rejection particularly in co-stimulation blockade–based
immunosuppressive regimens. Here we show that the CD2-specific fusion protein alefacept
(lymphocyte function–associated antigen-3–Ig; LFA-3–Ig) selectively eliminates memory T
cells and, when combined with a co-stimulation blockade–based regimen using cytotoxic T
lymphocyte antigen-4 (CTLA-4)-Ig, a CD80-and CD86-specific fusion protein, prevents renal
allograft rejection and alloantibody formation in nonhuman primates. These results support …
Abstract
Memory T cells promote allograft rejection particularly in co-stimulation blockade–based immunosuppressive regimens. Here we show that the CD2-specific fusion protein alefacept (lymphocyte function–associated antigen-3–Ig; LFA -3–Ig) selectively eliminates memory T cells and, when combined with a co-stimulation blockade–based regimen using cytotoxic T lymphocyte antigen-4 (CTLA-4)-Ig, a CD80- and CD86-specific fusion protein, prevents renal allograft rejection and alloantibody formation in nonhuman primates. These results support the immediate translation of a regimen for the prevention of allograft rejection without the use of calcineurin inhibitors, steroids or pan–T cell depletion.
nature.com